Frontlight ResearchEarly access
CompletedNo phase
Platelet Rich Plasma Versus Corticosteroids in Knee Osteoarthritis Pain
Key facts
- Who runs it
- LifeBridge Health
- Where
- Baltimore, United StatesSee the site
- Trial code
- Status
- Completed
- People taking part
- 52 people enrolled
- Started
- 2 Feb 2022
- Ended
- 16 Jul 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Corticosteroid Injection
- Platelet Rich Plasma Joint Injection
- Record updated
- 25 November 2024
Who can take part
- Age
- 21 years to 80 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Provision of signed and dated informed consent form
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Male or female, aged 21-80 years
- Radiographic diagnosis of Kellgren-Lawrence (KL) grade of II or III knee osteoarthritis
- Indicated for a knee injection to treat knee OA symptoms
Who cannot take part
- Current or previous diagnosis of "chronic pain"
- Treatment with another investigational drug or other intervention for pain
- Current overlying skin infection
- Allergy to any potential ingredients or medications utilized in any of the two groups
- Diagnosis of Diabetes Mellitus
- Any condition(s) or diagnosis, both physical or psychological, or physical exam finding in the opinion of the investigator that would precludes participation
- Any injections into the target knee within three months
- Opioid tolerant at time of screening (for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid.)
- If female, pregnant or planning to be pregnant within the following 3 months or study duration
Where in United States
- Sinai Hospital of BaltimoreBaltimore, United States
About the trial
What the trial wants to find out
Prospective, multi-center, randomized trial comparing platelet rich plasma (PRP) versus corticosteroid injection for the treatment of symptoms of knee osteoarthritis. The purpose of the study is to determine which therapy provides a greater reduction in patient reported outcome measures of pain and function.
The 2 groups in the trial
- Autologous Platelet Rich PlasmaTreatment being tested
\~3 milliliters (mL) injection of autologous PRP prepared with the Magellan Autologous Concentration System, ISTO Biologics
Treatment: Platelet Rich Plasma Joint Injection
- CorticosteroidExisting treatment, for comparison
5 milliliters (mL) injection of corticosteroid (1cc Kenalog, 4cc Xylocaine) Kenalog - 40 (triamcinolone acetonide injectable suspension, USP) Xylocaine - MPF (lidocaine HCl Injection, USP)
Treatment: Corticosteroid Injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The Efficacy of Platelet Rich Plasma Compared with Corticosteroid Injections for the Treatment of Pain Associated with Knee Osteoarthritis
- Record updated
- 25 November 2024